Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19.
Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19.
复制标题
DOI：
10.1073/pnas.2105815118
复制
发表时间：
2021-09-07
影响因子：
11.1
通讯作者：
Sexton JZ
中科院分区：
文献类型：
--
作者：
Mirabelli C;Wotring JW;Zhang CJ;McCarty SM;Fursmidt R;Pretto CD;Qiao Y;Zhang Y;Frum T;Kadambi NS;Amin AT;O'Meara TR;Spence JR;Huang J;Alysandratos KD;Kotton DN;Handelman SK;Wobus CE;Weatherwax KJ;Mashour GA;O'Meara MJ;Chinnaiyan AM;Sexton JZ
Since its emergence in China in December 2019, SARS-CoV-2 has caused a global pandemic. Repurposing of FDA-approved drugs is a promising strategy for identifying rapidly deployable treatments for COVID-19. Herein, we developed a pipeline for quantitative, high-throughput, image-based screening of SARS-CoV-2 infection in human cells that led to the identification of several FDA-approved drugs and clinical candidates with in vitro antiviral activity. The global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the associated disease COVID-19, requires therapeutic interventions that can be rapidly identified and translated to clinical care. Traditional drug discovery methods have a >90% failure rate and can take 10 to 15 y from target identification to clinical use. In contrast, drug repurposing can significantly accelerate translation. We developed a quantitative high-throughput screen to identify efficacious agents against SARS-CoV-2. From a library of 1,425 US Food and Drug Administration (FDA)-approved compounds and clinical candidates, we identified 17 hits that inhibited SARS-CoV-2 infection and analyzed their antiviral activity across multiple cell lines, including lymph node carcinoma of the prostate (LNCaP) cells and a physiologically relevant model of alveolar epithelial type 2 cells (iAEC2s). Additionally, we found that inhibitors of the Ras/Raf/MEK/ERK signaling pathway exacerbate SARS-CoV-2 infection in vitro. Notably, we discovered that lactoferrin, a glycoprotein found in secretory fluids including mammalian milk, inhibits SARS-CoV-2 infection in the nanomolar range in all cell models with multiple modes of action, including blockage of virus attachment to cellular heparan sulfate and enhancement of interferon responses. Given its safety profile, lactoferrin is a readily translatable therapeutic option for the management of COVID-19.
登录
查看更多内容
影响因子：
8.8
作者：
Dittmar M;Lee JS;Whig K;Segrist E;Li M;Kamalia B;Castellana L;Ayyanathan K;Cardenas-Diaz FL;Morrisey EE;Truitt R;Yang W;Jurado K;Samby K;Ramage H;Schultz DC;Cherry S
通讯作者：
Cherry S
影响因子：
64.5
作者：
Bouhaddou, Mehdi;Memon, Danish;Krogan, Nevan J.
通讯作者：
Krogan, Nevan J.
轻度疾病严重程度的 COVID-19 患者的消化道症状：临床表现、粪便病毒 RNA 检测和结果
影响因子：
9.8
作者：
Han, Chaoqun;Duan, Caihan;Hou, Xiaohua
通讯作者：
Hou, Xiaohua
影响因子：
23.9
作者：
Hurley, Killian;Ding, Jun;Kotton, Darrell N.
通讯作者：
Kotton, Darrell N.
影响因子：
3.1
作者：
Chen, Wei;Li, Xiao-ming;Hu, Han-ning
通讯作者：
Hu, Han-ning